|
PGXL Labs, AutoGenomics to expand molecular testing in
pharmacogenetics
May 2011
SHARING OPTIONS:
LOUISVILLE, K.Y.—PGXL Laboratories, a provider of
pharmacogenetic testing and
interpretive services, recently announced that it
has established a collaborative partnership with AutoGenomics Inc., a developer
of an automated, microarray-based multiplexing diagnostic
platform, wherein
they will utilize this platform—the automated INFINITI analyzer—for several
different personalized medicine applications.
PGXL plans to utilize the INFINITI Warfarin and CYP450 2C19
Assay and the INFINITI KRAS-BRAF test.
PGXL Labs was the first CLIA-certified lab in the country to
conduct pharmacogenetic tests. It provides pharmacogenetic testing and interpretive
services and developed one of the first commercial CYP2C9/VKORC1 tests for
accurate anticoagulant dosing. Along with its clinical practice, PGXL
performs
contract research for manufacturers of pharmaceuticals and medical equipment.
"The
automation provided by the AutoGenomics' INFINITI
Analyzer will enhance workflow in our laboratories," said Mark Linder,
executive vice president of
operations and co-founder of PGXL Labs, in a
statement. "With their comprehensive menu of molecular applications in the
pharmacogenetics arena, we
have found AutoGenomics to be a very suitable
partner in meeting our emerging testing needs."
A
privately held company based in Vista, Calif.,
AutoGenomics' technology can be used to assess disease signatures with novel genomic
and proteomic
markers in the area of genetic disorders, infectious disease,
cancer and pharmacogenetics.
"We are
excited to partner with PGXL Labs, who have
pioneered in bringing the benefits of pharmacogenetics testing to patients
across the country," stated
Ramanath Vairavan, senior vice president of
AutoGenomics. "The versatility of our BioFilmChip Microarray technology allows
us to rapidly develop new
test applications to meet the evolving needs in
companion diagnostic testing and enable PGXL Labs to expand the array of personalized
medicine tests.
"
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|